Drug Profile
Gestelmir
Alternative Names: GSE24.2 peptideLatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Institute of Biomedical Research Alberto Sols
- Developer Advanced Medical Projects
- Class Peptides
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyskeratosis congenita
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Dyskeratosis congenita in Spain (Parenteral) (http://www.advmedprojects.com/)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Dyskeratosis-congenita in Spain (Parenteral)